Medicare Price Negotiation: Special Treatment For ‘Novel Technologies’ On PhRMA’s Advocacy Agenda
Executive Summary
Novartis CEO Vasant Narasimhan, PhRMA's incoming board chair, says in an interview that the brand drug association has a slate of issues to pursue as it works to shape the implementation of the Medicare price negotiation program in the name of preserving innovation.
You may also be interested in...
President Biden’s Proposal To Expand Medicare Price Controls A Sign Of Things To Come
Even though it is unlikely that the policies will succeed in the currently divided Congress, the proposal reinforces industry’s concerns that once a foundation for Medicare price negotiation is established, policymakers will try to build on it.
UPDATED: US FDA Has People Working At CMS To Help Implement Inflation Reduction Act
The FDA was mum on the expertise that it appears to be lending the payer, but Commissioner Robert Califf reiterated that communication between the agency and CMS is increasing.
Inflation, Biosimilars, And The Wizard Of Oz: An Interview With Teva’s Christine Baeder
The new chair of the US generics association talks to the Pink Sheet about how to make sure that policymakers don’t take the industry for granted.